Other
T Cell Therapy
0
Pipeline Programs↗
10
Active Trials↗
1
Companies Involved↗
T Cell Therapy is an early-stage landscape with 0 programs across 1 company. The most active players are Chimeric Therapeutics.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
18
clinical trials
Recruiting7 · 39%
Unknown status5 · 28%
Completed3 · 17%
Not yet recruiting2 · 11%
Enrolling by invitation1 · 6%
Clinical Trials
Trial Activity
18 trials
Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL
Recruiting·—·Phase 1/2·NCT06321289·30 enrolled
Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
Recruiting·—·Phase 1/2·NCT06947473·45 enrolled
Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
Recruiting·—·Phase 1/2·NCT06838832·30 enrolled
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
Recruiting·—·Phase 1/2·NCT06947460·45 enrolled
Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL
Recruiting·—·Phase 1/2·NCT05554939·30 enrolled
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Not yet recruiting·—·Phase 1·NCT07374029·30 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)